Notice Regarding Recognition of Extraordinary Loss and Differences Between Full-Year Consolidated Earnings Forecast and Actual Results for the Fiscal Year

Key Points on Performance and Extraordinary Loss

By resolution published today, an impairment loss on advance payments was recorded as an extraordinary loss. The monetization policy for the solar power generation business, including properties held by F4, was revised, and a new policy was adopted that combines post-construction power sales, asset sales, and conversion to low-voltage system storage facilities. As a result, differences arose between the full-year consolidated earnings forecast for the fiscal year ending September 2026 and actual results, and the total extraordinary loss amounted to 983,964 thousand yen, recognized as an impairment.

Future Business Development and Outlook

In light of the impairment processing for the Cure brand, going forward the Company will combine development, ownership, and sale of solar power plants and storage facilities to monetize each asset according to its characteristics. The Company will also promote M&A and capital and business alliances to expand domestic and overseas sales channels and strengthen the revenue base. Aiming for recovery from fiscal 2027 onward, efforts will focus on increasing customer attraction and optimizing store operations.